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Abstract The fat mouse strain exhibits a late-onset obesity 
syndrome associated with a mutation in the gene encoding 
carboxypeptidase E (CPE). Since CPE plays a central role in the 
biosynthesis of a number of regulatory peptides, including 
gastrin, we examined the biogenesis and processing of progastrin 
in fatlfat mice by measuring gastrin mRNA, carboxyamidated 
gastrin and its processing intermediates in the stomach. The 
tissue concentration of carboxyamidated (i.e. bioactive) gastrin 
was only slightly reduced (601 ± 28 pmol/g in fatlfat mice vs. 
715 ±43 pmol/g in wild-type controls). However, progastrin 
processing intermediates accumulated excessively with an 86-fold 
increase in the concentration of the CPE substrate, glycyl-
arginine extended gastrin, and a seven-fold increase in the 
concentration of glycine-extended gastrin. Accordingly, the total 
progastrin product was doubled, as was the concentration of 
gastrin mRNA. Plasma concentrations of carboxyamidated 
gastrin were, however slightly reduced both in fasted fatlfat 
mice and postprandially. The results show that the CPE mutation 
diminishes the efficiency of progastrin processing, but gastrin 
synthesis is nevertheless increased to maintain an almost normal 
production of bioactive gastrins. By comparison with other 
neuroendocrine prohormones, progastrin processing in CPE-
deficient mice is unique. Hence, the increase of glycine-extended 
gastrin in combination with normal levels of carboxyamidated 
gastrin suggests that G-cells may have another biosynthetic 
pathway for gastrin. 
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1. Introduction 
Peptide hormones and neurotransmitters are synthesized as 
propeptides that undergo a series of modifications in the 
trans-Golgi network and the secretory vesicles before they 
are released as active peptides. The modifications include 
endo- and exoproteolytic cleavages, sulfation, phosphoryl-
ation, amidation and others. Prohormone convertases catalyze 
cleavages at di- and monobasic sites [1-3] with subsequent 
trimming by a carboxypeptidase to remove C-terminal basic 
residues [4,5]. 
Recently the fat mouse mutant was identified as one of the 
first in vivo models containing a mutation in a prohormone 
processing enzyme. The fat mutation is a missense mutation 
(Ser202Pro) in the carboxypeptidase E (CPE) gene, which ap-
pears to abolish enzyme activity [6]. The resulting phenotype 
is a slowly developing adult-onset obesity with mild diabetes 
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[6,7]. CPE is involved in the posttranslational maturation of 
many regulatory peptides. Thus, peptides requiring C-terminal 
trimming of basic residues may be deficient in this mouse 
mutant. Accordingly, fatlfat mice exhibit changes in the proc-
essing of proinsulin, prodynorphin, proneurotensin, promela-
nin-concentrating hormone and pro-opiomelanocortin show-
ing accumulation of hormone precursors and a marked 
decline in the production of bioactive peptides [6,8-10]. How-
ever, it is difficult to predict the complete range of peptides 
affected in the fatlfat mouse since carboxypeptidase D may 
compensate for CPE in some tissues [9,11]. 
Cellular synthesis of the gastrointestinal hormone, gastrin, 
also requires carboxypeptidase cleavage (Fig. 1). Progastrin 
processing involves endoproteolytic cleavage by prohormone 
convertases yielding a C-terminally glycyl-arginine extended 
gastrin, which by carboxypeptidase removal of the arginyl 
residues exposes glycine-extended gastrin for amidation [12]. 
Using the fat mouse as an in vivo model, we have now tested 
the hypothesis that CPE is required for the maturation of 
gastrin. Moreover, we examined how alterations in progastrin 
processing might change the biosynthesis to ameliorate the 
effects of reduced maturation. Finally, we measured plasma 
concentrations of amidated (i.e. bioactive) gastrin to deter-
mine if fatlfat mice responded adequately to food. 
2. Materials and methods 
2.1. Mice 
Heterozygous fatl+ mice were purchased from The Jackson Labo-
ratory (Bar Harbor, ME). Homozygous fatlfat and wild-type (+/+) 
mice were generated by intercrossing heterozygotes and genotyping 
the offspring. Mice were housed on a 12 h light-dark cycle and fed 
Purine 5008 chow ad lib. 
2.2. Genotyping 
Genomic DNA was prepared from tail biopsies [13]. The fat and 
wild-type CPE alleles were detected using an allele-specific polymerase 
chain reaction (PCR) assay. Primer CPE-R (5' CGC TCC GTG TCT 
CAT CAT ATG GGT AAT) was paired with primer WT (5' GGA 
CAT TCC ATT TGT GCT TT) or FAT (5' GGA CAT ТСС АТТ 
TGT GCT TC) to amplify an 80 bp fragment from the wild-type or 
fat alleles, respectively. (Underlined primer sequences highlight the 
single nucleotide difference between the two alleles.) PCR reactions 
contained 10 mM Tris-HCl, pH 8.3; 50 mM KC1; 3.5 mM (WT) or 
3 mM (FAT) MgCl2; 0.01% (w/v) bovine serum albumin; 0.2 mM 
dATP, dCTP, dGTP and dTTP; Taq polymerase; and 1.0 μΜ (CPE-
R, FAT) or 2.0 μΜ (WT) primers. The cycle parameters were: (i) 94°C 
5 min, (ii) 40 cycles of 94°C 45 s, 62°C 45 s, 72°C 1 min, (iii) 72°C 
3 min. The amplified products were detected by electrophoresis in 5% 
agarose [3:1 NuSieve GTG (FMC BioProducts) : ultra PURE agarose 
(Gibco-BRL)] and ethidium bromide staining. 
2.3. Tissue isolation and extraction 
Eight mice 2-6 months old were anesthetized, and stomach tissue 
was rapidly dissected and frozen in liquid nitrogen. The tissue was 
gently cleaned in phosphate buffered saline, on ice, before freezing. 
Tissue extracts for radioimmunoassay (RIA) were prepared as previ-
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Fig. 1. Diagrammatic presentation of the co- and posttranslational modification of preprogastrin in the stomach. Activation of the gastrin ami-
dation site (R1-Phe-Gly-Arg-Arg-R2) occurs via a series of carboxy-terminal cleavages and modifications. Endoproteolytic cleavage by prohor-
mone convertases produces the carboxypeptidase E substrate (Ri-Phe-Gly-Arg). Carboxypeptidase E then acts in secretory granules to remove 
the C-terminal arginine residue yielding glycine-extended gastrin (Ri-Phe-Gly). Carboxyamidation of glycine-extended gastrin by a-amidating 
mono-oxygenase results in the production of bioactive gastrin (Ri-Phe-NH2). Concomitant N-terminal cleavage by prohormone convertases 
produces pro- and bioactive gastrins of varying sizes (e.g. gastrin-71, gastrin-34, etc.). A library of sequence-specific antibodies was used in 
combination with in vitro protease treatments to measure bioactive gastrin and various precusor peptides, as described in Section 2. 
ously described [14]. Briefly, frozen tissues were boiled in water (1 ml/ 
mg) for 20 min, homogenized (polytron) and centrifuged for 30 min at 
10000 rpm. The supernatants were withdrawn and the pellets re-ex-
tracted in 0.5 M CH3COOH (1 ml/mg), rehomogenized, incubated at 
room temperature for 30 min and centrifuged. The water and acid 
supernatants were stored at —20°C until RIA analysis. 
2.4. Chromatography 
One or two ml of extracts were applied to Sephadex G-50 superfine 
column (10 X 1000 mm), which were eluted at 4°C with 0.02 M barbi-
tal buffer, pH 8.4, containing 0.1% bovine serum albumin. Fractions 
of 1.0 ml were collected at a rate of 4.0 ml/h. The columns were 
calibrated with [125I]albumin (void volume), human gastrin-71, -34 
and -17 (both sulfated (s) and non-sulfated (ns) gastrin-17), and 
with 22NaCl (total volume). The elutions were monitored with se-
quence-specific radioimmunoassays as described below. 
2.5. Radioimmunoassay 
A library of sequence-specific antibodies against progastrin was 
used to measure the different forms of gastrin and its processing 
intermediates (Fig. 1). The sum of carboxyamidated, bioactive gastrin 
were measured using the gastrin-specific antiserum no. 2604, with 
[125I]gastrin-17 as tracer and gastrin-17 as standard [15]. Antibody 
no. 2604 binds all the carboxyamidated forms of gastrin with equi-
molar affinity irrespective of size and sulfation. Crossreactivity with 
homologous cholecystokinin (CCK) peptides is negligible [15]. Non-
sulfated carboxyamidated gastrins were measured in parallel using 
antibody no. 2605 [16]. Glycine-extended intermediates of gastrin 
were measured using antiserum no. 3208 with [125I]glycine-extended 
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Fig. 2. Gel chromatography on Sephadex G-50 superfine columns of stomach extracts from wild-type control mice (left) and the CPE-mutant 
fatlfat mice (right). The upper panels show the elution of carboxyamidated gastrins as measured using Ab. no. 2604 ( · ) , which binds both sul-
fated and non-sulfated gastrins and Ab. no. 2605 (o), which binds only non-sulfated gastrins. The lower panels show the elution of glycine-ex-
tended gastrins (Ab. no. 3208, o ) and further C-terminally extended gastrins (Ab. no. 3208 after trypsin and carboxypeptidase В treatment, · ) . 
The arrows indicate the elution positions of corresponding human gastrins used for calibration. 
gastrin-17 as tracer and glycine-extended gastrin-17 as standard [17]. 
Glycine-arginine-extended intermediate precursors were measured us-
ing antiserum no. 3208 following enzymatic pretreatment with carbox-
ypeptidase В (СРВ). То measure all three precursor forms of gastrin, 
samples were pretreated with trypsin and СРВ followed by RIA with 
antiserum no. 3208, as described previously [17]. СРВ mimics the 
effect of CPE, while trypsin mimics the effects of prohormone con-
vertase. Control measurements of homologous CCK peptides were 
performed with a CCK-specific RIA using the new antibody no. 
92128 (Rehfeld, unpublished). 
2.6. RNA analysis 
Tissue for RNA analysis was isolated from animals fasted over-
night. Total RNA was extracted from frozen tissue by a guanidine 
thiocyanate homogenization-CsCl centrifugation method [18]. For 
Northern blot analysis, total stomach RNA samples (10 μg) were 
electrophoresed in agarose gels containing 2.2 M formaldehyde and 
transferred to Zeta-Probe nylon membrane (BioRad). Probes were 
32P-labeled and hybridized to filters as previously described [19]. Final 
wash conditions were 0.5XSSC (0.075 M NaCl, 7.5 mM trisodium 
citrate, pH 7.0) and 0.1% SDS at 60°C. Imaging and quantitation 
were performed on a GS-250 Molecular Imager (BioRad). The gastrin 
probe was a 422 bp cDNA [20]. After hybridization, filters were 
stripped and rehybridized with a mouse ribosomal protein L32 probe 
[21] to control for RNA loading. 
2.7. Plasma hormone measurements 
To examine changes in circulating gastrin concentrations in re-
Table 1 
Progastrin peptide products in the stomach horn fatlfat and wild-type mice (pmol per g tissue (wet weight); mean±S.E.M., 
Peptide Wild-type fatlfat 
Carboxyamidated gastrins 
sulfated 
non-sulfated 
total amidated 
C-terminally extended gastrins 
glycine-extended 
glycine-arginine-extended 
further extended 
Total progastrin product 
506 ±37 
209 ±11 
715±43 
4.8 ±0.5 
12.2 ±6.3 
11.6±5.2 
744 
413±31 
188± 17 
601 ±28 
34.7 ±7.1 
1054 ±122 
0 
1690 
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sponse to feeding, mice were fasted for 24 h before blood collection by 
retro-orbital bleeding. A second group of mice was fasted and then 
refed for 40 min before bleeding. Blood was collected into tubes con-
taining 10 mM EDTA. Plasma concentrations of carboxyamidated 
gastrins were measured radioimmunochemically using antibody no. 
2604 as previously described [15,22]. 
2.8. Statistics 
Statistical analysis was carried out using an unpaired i-test with the 
SYSTAT software. All values are expressed as means ± S.E.M. 
3. Results 
3.1. Progastrin processing 
The concentrations of carboxyamidated (i.e. bioactive) gas-
trins in the stomach was insignificantly lower in fati fat mice 
compared to wild-type controls (Table 1). A large percentage 
of carboxyamidated gastrins are sulfated in normal mice 
(71%, Table 1). The similar degree of sulfation in fat mice 
(69%) indicates that the early posttranslational modification 
by tyrosyl-protein sulfotransferase is unaffected by CPE. To 
determine the effect of the CPE mutation on further progas-
trin processing, we measured the concentrations of a number 
of processing intermediates (Fig. 1) in gastric extracts. In con-
trast to the almost normal concentration of carboxyamidated 
gastrin, those of some progastrin processing intermediates 
were grossly increased in the mutant. The concentration of 
the progastrin-derived substrate for CPE, glycyl-arginine-ex-
tended gastrin, was 86-fold elevated in fat/fat mice (12.2 vs. 
1054.0 pmol/g, Table 1). Surprisingly the concentration of 
glycine-extended gastrin was also markedly increased (from 
4.8 to 34.7 pmol/g, Table 1). In contrast fat/fat mice were 
apparently devoid of further C-terminal extended gastrin (Ta-
ble 1). Summing up the total progastrin product, fat I fat 
mouse stomachs contain twice the amount of wild-type con-
trols. 
Gel chromatography showed marked differences in the N-
terminal proteolytic processing of progastrin in fat/fat and 
wild-type mice (Fig. 2). Carboxyamidated, glycine-extended 
Fig. 3. Plasma concentrations of carboxyamidated bioactive gastrins 
in fasted and refed mice. Fasted mice were food deprived for 24 h, 
and refed mice were fasted then refed for 40 min before plasma col-
lection. Open bars represent fasted mice and solid bars represent 
refed mice. The mean values and S.E.M. are expressed as pmol per 
liter plasma. The number of mice is shown for each group in paren-
theses. *P<0.01; tP<0.05. 
Fig. 4. Gastrin mRNA abundance in fat/fat mice. Displayed are the 
results from Northern blot analysis of stomach RNA hybridized 
with a gastrin probe from two wild-type (+/+) and two fat/fat (flf) 
mice. The top half shows hybridization with the gastrin probe, while 
the bottom half shows the same filters after stripping and rehybrid-
izing with the rpl32 probe to control for loading. 
and glycyl-arginine-extended gastrins were cleaved at N-termi-
nal processing sites to a greater extent in fat!fat mice, so that 
shorter molecular forms constituted a larger fraction of the 
progastrin products. The molecular pattern suggests that CPE 
influences endoproteolytic prohormone convertase cleavage, 
but not the early tyrosyl protein sulfotransferase modification 
(Table 1, Figs. 1 and 2). 
3.2. Plasma gastrin 
The basal plasma concentration of carboxyamidated gastrin 
in fat mice was not insignificantly lower than in wild-type 
controls (Fig. 3). To examine whether fat/fat mice exhibit 
the normal postprandial rise, we also measured gastrin con-
centrations in plasma after refeeding. In wild-type mice gas-
trin concentrations significantly increased 40 min after refeed-
ing. However, this response was attenuated in fat/fat mice. 
Although circulating gastrin concentrations in fat/fat mice 
rose after refeeding, postprandial concentrations were 2.4-
fold lower than in the control mice. 
3.3. Gastrin mRNA levels 
Gastrin transcript levels measured by Northern blot analy-
sis were two-fold higher in fat/fat mice (P < 0.05 ; n — 4 per 
group) (Fig. 4). This is in accordance with the two-fold in-
crease in progastrin processing intermediates (Table 1). 
4. Discussion 
The results of this study demonstrate that CPE is heavily 
involved in the maturation of progastrin. However, the proc-
essing differs from that of other prohormones examined so far 
[6,8-10], as CPE-deficient mice are able to maintain essentially 
normal tissue concentrations of bioactive oc-carboxyamidated 
gastrin. Analysis of gastrin processing revealed a marked in-
crease in some precursor peptides, including the excessive 86-
fold accumulation of glycyl-arginine-extended gastrin. We ex-
pected the defect in carboxypeptidase activity to result in an 
accumulation of glycyl-arginine-extended gastrin, since this is 
the substrate for CPE. Previous studies in fat/fat mice dem-
onstrated reduced levels of mature peptides, such as insulin, 
neurotensin, melanin-concentrating hormone, dynorphin and 
ACTH, with a more modest accumulation of arginine-ex-
tended peptides [6,8-10], and with no significant changes in 
other processing intermediates. We have also found such 
processing abnormalities for cholecystokinin, a hormone ho-
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mologous to gastrin (unpublished). Further examination of 
gastrin processing revealed an unexpected seven-fold accumu-
lation of glycine-extended gastrin and the absence of other C-
terminally extended gastrin precursors. The massive accumu-
lation of gastrin processing intermediates indicates that gas-
trin biosynthesis is upregulated in the mutant to compensate 
for the processing deficiency. Thus, the effects of CPE dys-
function on progastrin processing appear to be unique in 
comparison with the processing of other prohormones. 
The seven-fold increase in glycine-extended gastrin is sur-
prising since this intermediate is the product of carboxypepti-
dase cleavage and thus expected to be readily amidated. The 
accumulation of glycine-extended gastrin indicates that the 
peptidylglycine α-amidating mono-oxygenase complex is not 
readily available for amidation following carboxypeptidase 
cleavage, suggesting an alternative processing pathway for 
progastrin in the fatlfat mutant. There are recent data to 
suggest that CPE may function as a sorting receptor to par-
tition peptides into the regulated secretory pathway [10]. Loss 
of sorting receptor in the fat mutant could result in the mis-
direction of progastrin into a different cellular compartment, 
removed from other modifying enzymes, producing more 
widespread disturbances in peptide processing than would 
be predicted from reduced carboxypeptidase activity alone. 
To investigate possible mechanisms for the upregulation of 
gastrin synthesis, we measured gastrin mRNA in the stomach 
and found that transcript levels doubled in fatlfat mice. This 
change in gastrin mRNA is similar to increases observed when 
gastric acid secretion is blocked by the H+/K+-ATPase antag-
onist, omeprazole, or by surgical removal of the acid-secretory 
portion of the stomach [23,24]. In these models, increased 
gastrin mRNA is also associated with hypergastrinemia, while 
in fatlfat mice, the plasma concentration of carboxyamidated 
gastrin was slightly reduced. The observed increase in gastrin 
mRNA in fatlfat mice could result from a proliferation of 
gastrin producing cells (G-cells), or from increased gene tran-
scription or mRNA stability. A prolonged state of gastric acid 
hyposecretion can lead to an increase in the number of G-cells 
in the gastric mucosa. Indeed, G-cell numbers are increased 
two-fold in a mutant mouse strain which does not express 
gastrin receptors [25]. Alternatively, an accumulation of tran-
scripts within individual G-cells could also lead to elevated 
gastrin mRNA levels. Somatostatin, the primary negative reg-
ulator of gastrin release, inhibits gastrin gene expression by 
decreasing transcription and mRNA stability [26-29]. Thus, a 
reduction in gastrin and gastric acid output in fatlfat mice 
could reduce somatostatin secretion, thereby lessening the in-
hibitory mechanisms regulating gastrin biosynthesis. How-
ever, we measured somatostatin in stomach extracts and 
found no differences between fatlfat mice and wild-type con-
trols (data not shown). 
During the preparation of this paper, Udupi et al. reported 
a similar study on gastrin processing in fatlfat mice [29]. Their 
results generally correspond to those presented here, but they 
deviate in two important respects. First, they did not measure 
glycine-extended gastrin, which is necessary for interpreting 
changes in G-cell processing caused by the CPE mutation. 
The unexpected increase in the concentration of glycine-ex-
tended gastrin found in our study (Table 1) is a key argument 
for the existence of an alternative processing pathway. In 
addition, the possible growth effects of glycine-extended gas-
trin [30,31] have drawn particular attention to its synthesis. 
Second, Udupi et al. found a significant reduction in the con-
centration of carboxyamidated gastrin. 
Maintaining physiologic concentrations of gastrin is impor-
tant for normal stomach function. Measurement of plasma 
concentrations showed that although the basal concentration 
of bioactive gastrin is normal in fatlfat mice, meal-stimulated 
gastrin secretion is attenuated. Forty minutes after a meal, 
gastrin concentrations were 2.4-fold lower in fatlfat mice com-
pared to controls. This reduction in postprandial gastrin levels 
suggests that meal-stimulated acid secretion may also be at-
tenuated. Thus, the attenuation of postprandial hormone se-
cretion in the fatlfat mouse suggests that the CPE processing 
defect may affect gastric function. 
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